NAFLD (nonalcoholic fatty liver disease) is a common illness that can develop to serious liver problems such hepatic fibrosis and hepatocellular cancer. Sedentary behaviour and a high-calorie diet are the most typical causes. There is currently no FDA-approved medicine to treat NAFLD in the United States, leaving only dietary changes, increased physical activity, exercise, and antioxidants as possibilities. The Drug Controller General of India (DGCI) authorised Saroglitazar Mg as a new drug application (NDA) to treat NAFLD in India in December 2020. The pathogenesis, diagnostic procedures, and prospective targets for NAFLD prevention and treatment are all detailed in this review.
Author (s) Details
Jarnail Singh Braich
Department of Pharmacology, Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak-124001 (IN), India.
View Book :- https://stm.bookpi.org/TIPR-V8/article/view/2209
No comments:
Post a Comment